Corrigendum: Patients with myeloproliferative neoplasms harbor high frequencies of CD8 T cell-platelet aggregates associated with T cell suppression

• Ana Micaela Carnaz Simões,
• Morten Orebo Holmström,
• Pia Aehnlich,
• Anne Rahbech,
• Marlies J. W. Peeters,
• Aneta Radziwon-Balicka,
• Carlos Zamora,
• Tobias Wirenfeldt Klausen,
• Vibe Skov,
• Lasse Kjær,
• Christina Ellervik,
• Christina Ellervik,
• Christina Ellervik,
• Daniel El Fassi,
• Daniel El Fassi,
• Silvia Vidal,
• Hans Carl Hasselbalch,
• Mads Hald Andersen,
• Mads Hald Andersen,
• Per thor Straten,
• Per thor Straten

Affiliations

Ana Micaela Carnaz Simões

Department of Oncology, National Center for Cancer Immune Therapy (CCIT-DK), Herlev University Hospital, Herlev, Denmark

Morten Orebo Holmström

Department of Oncology, National Center for Cancer Immune Therapy (CCIT-DK), Herlev University Hospital, Herlev, Denmark

Pia Aehnlich

Department of Oncology, National Center for Cancer Immune Therapy (CCIT-DK), Herlev University Hospital, Herlev, Denmark

Anne Rahbech

Department of Oncology, National Center for Cancer Immune Therapy (CCIT-DK), Herlev University Hospital, Herlev, Denmark

Marlies J. W. Peeters

Department of Oncology, National Center for Cancer Immune Therapy (CCIT-DK), Herlev University Hospital, Herlev, Denmark

Aneta Radziwon-Balicka

Department of Oncology, National Center for Cancer Immune Therapy (CCIT-DK), Herlev University Hospital, Herlev, Denmark

Carlos Zamora

IIB-Sant Pau- Institut Rec. Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

Tobias Wirenfeldt Klausen

Department of Oncology, National Center for Cancer Immune Therapy (CCIT-DK), Herlev University Hospital, Herlev, Denmark

Vibe Skov

Department of Hematology, Zealand University Hospital, Roskilde, Denmark

Lasse Kjær

Department of Hematology, Zealand University Hospital, Roskilde, Denmark

Christina Ellervik

Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

Christina Ellervik

Department of Laboratory Medicine, Boston Children’s Hospital, Harvard Medical School, Boston, MA, United States

Christina Ellervik

Department of Data and Innovation Support, Region Zealand, Sorø, Denmark

Daniel El Fassi

Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

Daniel El Fassi

Department of Hematology, Rigshospitalet University Hospital, Copenhagen, Denmark

Silvia Vidal

IIB-Sant Pau- Institut Rec. Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

Hans Carl Hasselbalch

Department of Hematology, Zealand University Hospital, Roskilde, Denmark

Mads Hald Andersen

Department of Oncology, National Center for Cancer Immune Therapy (CCIT-DK), Herlev University Hospital, Herlev, Denmark

Mads Hald Andersen

Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

Per thor Straten

Department of Oncology, National Center for Cancer Immune Therapy (CCIT-DK), Herlev University Hospital, Herlev, Denmark

Per thor Straten

Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark